Mainbayar Badarch
Latest From Mainbayar Badarch
China’s CAR T-Cell Therapy Industry Booms With Shanghai At Center
According to China Pharmaceutical Innovation and Research Development Association, in the first quarter of 2024 a total of 44 cell therapies in the domestic cell therapy field made clinical application progress, including 28 immune cell therapies and 16 stem cell therapies.
South Korea Sees Pharma Leadership Transition
Leadership succession is proceeding within South Korean pharmaceutical corporations such as Daiichi Sankyo Korea, Astellas Pharma Korea, Kyowa Kirin Korea as well as MSD Korea.
China: Value-Based Procurement Reshapes Strategies Of Multinational Medtech Firms
China’s growing market for medtech, estimated at $70bn in 2021, could more than double this decade if the government’s Healthy China 2030 plan stays on track.
China: Value-Based Procurement Reshapes Strategies Of Multinational Medtech Firms
China’s growing market for medtech, estimated at $70bn in 2021, could more than double this decade if the government’s Healthy China 2030 plan stays on track.
Asian Giants Are Racing For Neuroscience Developments
China, Japan and South Korea are the top economic powerhouses of Asia. They compete not only for production industries such as electronics, but also for medical sciences. China has enormous resources compared with the two other nations.
China’s Cancer Market Is Evolving Fast, Four Multinationals Dominate
In the Chinese pharmaceutical market, sales of anti-tumor drugs have been showing a steady growth trend in recent years as cancer patient numbers continue to rise.